| Description | MethADP (Adenosine 5'-(α,β-methylene)diphosphate) is a specific CD73 inhibitor that inhibits the enzyme ecto-5′-nucleotidase (ecto), which has been used in the study of neurological and cardiovascular diseases. |
| In vitro | MethADP (AMP-CP: 20 μM) causes a marked inhibition of adenosine formation (0.96±0.96 μM) compared to untreated controls (9.6±1.5 μM) in A498 and RT4 cells, and MethADP (100 μM) completely inhibits the adenosine formation. |
| Synonyms | Adenosine 5'-(α,β-methylene)diphosphate |
| molecular weight | 425.23 |
| Molecular formula | C11H17N5O9P2 |
| CAS | 3768-14-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Mohlin C, et al. Studies of the extracellular ATP-adenosine pathway in human urinary tract epithelial cells. Pharmacology. 2009;84(4):196-202. 2. Shi E, Wu Z, Karaoglan BS, Schwenk-Zieger S, Kranz G, Abdul Razak N, Reichel CA, Canis M, Baumeister P, Zeidler R, Gires O. 5'-Ectonucleotidase CD73/NT5E supports EGFR-mediated invasion of HPV-negative head and neck carcinoma cells. J Biomed Sci. 2023 Aug 24;30(1):72. |